What Is Next for COVID-19 Vaccination?

IF 2.3 3区 医学 Q2 CRITICAL CARE MEDICINE
Antoni Trilla, Guillem Trilla, Marta Aldea, Anna Vilella
{"title":"What Is Next for COVID-19 Vaccination?","authors":"Antoni Trilla, Guillem Trilla, Marta Aldea, Anna Vilella","doi":"10.1055/a-2531-1211","DOIUrl":null,"url":null,"abstract":"<p><p>Whenever a new COVID-19 vaccination season starts, we must face new challenges, including which vaccines to use, the update of the high-risk groups to be vaccinated, and especially the type and amount of information to be communicated to people in order to promote vaccination. COVID-19 vaccination recommendations should fit these specific conditions. The use of effective vaccines against the predominant SARS-CoV-2 virus variants and the extent of the immune response (waning immunity) are key aspects to try to protect better the high-risk populations. Updated vaccines are currently swiftly available. However, the number of people vaccinated with any additional booster dose is declining. Improved health information and training for health care professionals, together with the use of better tools to make simpler vaccination recommendations, can encourage higher vaccination rates. Addressing these challenges is essential to improve vaccination coverage and ensure adequate protection in the face of evolving COVID-19 threats. The SARS-CoV-2 virus has become a constant presence in our society. The virus changes but is neither endemic nor seasonal so far. The Omicron variant prevailed for nearly 2 years and now several of its subvariants like JN.1, KP.2, or XEC are or can be the dominant ones. In the face of this moving situation, the main message must be the same: COVID-19 vaccines are safe and effective. The role of current COVID-19 vaccination efforts is to mitigate the severity of the disease and reduce the risk of complications and death, instead of preventing most SARS-CoV-2 infections. New vaccines against COVID-19 are now at different stages of clinical research.</p>","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2531-1211","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Whenever a new COVID-19 vaccination season starts, we must face new challenges, including which vaccines to use, the update of the high-risk groups to be vaccinated, and especially the type and amount of information to be communicated to people in order to promote vaccination. COVID-19 vaccination recommendations should fit these specific conditions. The use of effective vaccines against the predominant SARS-CoV-2 virus variants and the extent of the immune response (waning immunity) are key aspects to try to protect better the high-risk populations. Updated vaccines are currently swiftly available. However, the number of people vaccinated with any additional booster dose is declining. Improved health information and training for health care professionals, together with the use of better tools to make simpler vaccination recommendations, can encourage higher vaccination rates. Addressing these challenges is essential to improve vaccination coverage and ensure adequate protection in the face of evolving COVID-19 threats. The SARS-CoV-2 virus has become a constant presence in our society. The virus changes but is neither endemic nor seasonal so far. The Omicron variant prevailed for nearly 2 years and now several of its subvariants like JN.1, KP.2, or XEC are or can be the dominant ones. In the face of this moving situation, the main message must be the same: COVID-19 vaccines are safe and effective. The role of current COVID-19 vaccination efforts is to mitigate the severity of the disease and reduce the risk of complications and death, instead of preventing most SARS-CoV-2 infections. New vaccines against COVID-19 are now at different stages of clinical research.

COVID-19疫苗接种的下一步是什么?
每当新的COVID-19疫苗接种季节开始时,我们都必须面临新的挑战,包括使用哪种疫苗,更新需要接种疫苗的高危人群,特别是要向人们传达的信息类型和数量,以促进疫苗接种。COVID-19疫苗接种建议应符合这些具体条件。使用针对主要SARS-CoV-2病毒变体的有效疫苗和免疫反应的程度(免疫力减弱)是试图更好地保护高危人群的关键方面。目前可以迅速获得更新的疫苗。然而,接种任何额外加强剂量疫苗的人数正在下降。改善卫生信息和对卫生保健专业人员的培训,以及使用更好的工具来提出更简单的疫苗接种建议,可以鼓励提高疫苗接种率。应对这些挑战对于提高疫苗接种覆盖率和确保在面对不断变化的COVID-19威胁时提供充分保护至关重要。SARS-CoV-2病毒已经成为我们社会中持续存在的病毒。这种病毒会发生变化,但迄今为止既不是地方性的,也不是季节性的。Omicron变体流行了将近2年,现在它的几个亚变体,如JN.1、KP.2或XEC是或可能是占主导地位的。面对这种变化的形势,主要信息必须是一样的:COVID-19疫苗是安全有效的。目前COVID-19疫苗接种工作的作用是减轻疾病的严重程度,降低并发症和死亡的风险,而不是预防大多数SARS-CoV-2感染。针对COVID-19的新疫苗目前处于临床研究的不同阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
87
审稿时长
6-12 weeks
期刊介绍: The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信